Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Positive for serum anti-HTLV-I antibody~2. Acute-, lymphoma-, or chronic-type with poor prognostic factors specified in the past~3. Positive for CCR4~4. Relapsed subject after the response (CR, CRu or PR) in the last previous chemotherapy~5. Received at least one prior chemotherapy~6. Subjects with an interval of four weeks or more between the last day of the previous treatment and the scheduled day of the first KW-0761 treatment~7. PS of 0 to 2~8. Negative for HBs antigen and for HBV-DNA by a real-time PCR~Exclusion Criteria:~1. A history of transplantation such as hematopoietic stem cells~2. Positive for HCV antibody or HIV antibody~3. Active multiple cancers at the time of starting this clinical study~4. Previous history of allergic reactions after receiving antibody products~5. Requiring continuous systemic treatment with a steroid~6. Requiring such radiotherapy after starting this clinical study~7. Treated with any investigational drug other than KW-0761 within three months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KW-0761 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).